Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?

Expert Review of Hematology

Volumn 3, Issue 4, 2010, Pages 369-372

  Bourquin, Jean Pierre ^a   Bornhauser, Beat ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

chemosensitization; drug resistance; leukemia; necroptosis

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLINATUMOMAB; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MONOCLONAL ANTIBODY; OBATOCLAX; RAPAMYCIN; RAZOXANE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGE DISTRIBUTION; APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; CELL DEATH; CHEMOSENSITIZATION; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EDITORIAL; EMERGENCY HEALTH SERVICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NEUROTOXICITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; STROMA CELL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRROLES;

EID: 77955627939     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.39     Document Type: Editorial

References (36)

1. Bader P, Kreyenberg H, Henze GH et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J. Clin. Oncol. 27(3), 377-384 (2009).
2. Gaynon PS, Angiolillo AL, Carroll WL et al. Long-term results of the childrens cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Childrens Oncology Group Report. Leukemia 24(2), 285-297 (2009).
3. Tallen G, Ratei R, Mann G et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J. Clin. Oncol. 28(14), 2339-2347 (2010).
4. Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115(16), 3206-3214 (2010).
5. Schrauder A, Stanulla M, Flohr T et al. Prospective evaluation of MRD-kinetics in 274 children with high-risk ALL treated in trial ALL-BFM 2000: insights into development of resistance and impact on further refinement of treatment stratification strategies. Blood 585a (2007).
6. Zwaan CM, Kearns P, Caron H et al. The role of the innovative therapies for children with cancer (ITCC) European consortium. Cancer Treat. Rev. 36(4), 328-334 (2010).
7. Houghton PJ, Morton CL, Tucker C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood Cancer 49(7), 928-940 (2007).
8. Bonapace L, Bornhauser BC, Schmitz M et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 120(4), 1310-1323 (2010).
9. Kharas MG, Janes MR, Scarfone VM et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118(9), 3038-3050 (2008).
10. le Viseur C, Hotfilder M, Bomken S et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 14(1), 47-58 (2008).
11. Liem NL, Papa RA, Milross CG et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103(10), 3905-3914 (2004).
12. Teachey DT, Obzut DA, Cooperman J et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107(3), 1149-1155 (2006).
13. Schmitz M, Mirkowska P, Breithaupt P et al. Leukemia-initiating cells are frequent in very high risk childhood acute lymphoblastic leukemia and give rise to relatively stable phenotypes in immunodeficient mice. Blood 114(22), 86a (2009).
14. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 51(5), 476-489 (2010).
15. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancers Achilles heel. Cancer Cell 13(6), 472-482 (2008).
16. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor. Blood 105(6), 2519-2526 (2005).
17. Bornhauser BC, Bonapace L, Lindholm D et al. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 110(6), 2084-2091 (2007).
18. Wei G, Twomey D, Lamb J et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10(4), 331-342 (2006).
19. Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042), 677-681 (2007).
20. Tse C, Shoemaker AR, Adickes J et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68(9), 3421-3428 (2008).
21. High LM, Szymanska B, Wilczynska-Kalak U et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 77(3), 483-494 (2010).
22. Lock R, Carol H, Houghton PJ et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood Cancer 50(6), 1181-1189 (2008). (Pubitemid 351555542)
23. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111(4), 2300-2309 (2008).
24. Buron N, Porceddu M, Brabant M et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PloS One 5(3), e9924 (2010).
25. Kang MH, Kang YH, Szymanska B et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110(6), 2057-2066 (2007).
26. Konopleva M, Contractor R, Tsao T et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10(5), 375-388 (2006).
27. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115(16), 3304-3313 (2010).
28. Nguyen M, Marcellus RC, Roulston A et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl Acad. Sci. USA 104(49), 19512-19517 (2007).
29. Degterev A, Hitomi J, Germscheid M et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4(5), 313-321 (2008).
30. Jaattela M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat. Immunol. 4(5), 416-423 (2003).
31. Bell BD, Leverrier S, Weist BM et al. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc. Natl Acad. Sci. USA 105(43), 16677-16682 (2008).
32. Hitomi J, Christofferson DE, Ng A et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135(7), 1311-1323 (2008).
33. Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68(19), 8022-8030 (2008).
34. OBrien SM, Claxton DF, Crump M et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113(2), 299-305 (2008).
35. Paik PK, Rudin CM, Brown A et al. A Phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-010-1265-5 (2010) (Epub ahead of print).
36. Schimmer AD. Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract. Res. Clin. Haematol. 221(1), 5-11 (2009).